Last checked at 
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Great Southern Copper PLC - London-based copper company focused in Chile - Identifies targets for its detailed prospect-scale exploration at its Especularita copper-gold project. Says that the targets show potential for high-grade vein-hosted gold and copper targets, as well as high-grade breccia-hosted copper and gold targets. "Especularita encompasses a very large mineral system. We have identified a broad range of deposit types and are highly encouraged by these early exploration results. The reconnaissance work is on-going and we expect to generate further exciting prospects in 2023," Chief Executive Officer Sam Garrett says.
----------
Guanajuato Silver Co Ltd - silver producer in Mexico - Delivers a total of 96,518 ounces of silver and 846 ounces of gold from its mines in Mexico. Reports the partial prepayment of the two silver and gold loan/pre-payment facilities with Swiss-based precious metals trading firm OCIM Precious Metals SA. "We look forward to continuing our excellent working relationship with OCIM as we continue to ramp-up production at all four of our producing silver mines in Mexico," Chair & Chief Executive James Anderson says.
----------
Galantas Gold Corp - Northern Ireland-focused gold producer - Appoints Micon International Ltd to produce a NI 43-101-compliant mineral resource estimate for its Omagh gold project in Northern Ireland. "We expect a proportion of the 2014 resources to be upgraded, and for gaps in the resource to be filled in. We are also excited for the dilation zones to be remodelled into the resource, and look forward to providing the new mineral resource estimate by Q2 2023," CEO Mario Stifano comments.
----------
Invinity Energy Systems PLC - London-based utility-grade energy storage manufacturer - Says that 99% of its shareholders voted for each issued ordinary share of EUR0.50 each to be subdivided into one share of EUR0.01 each and one deferred A share of EUR0.49 each at its extraordinary general meeting for the purpose of reorganising its capital. Adds that 99% of its shareholders voted for the new articles to be adopted as the company's articles of association.
----------
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Reports that the Bundesamt fur Sicherheit im Gesundheitswesen cleared its clinical trial application for AT278, an ultra-rapid acting, ultra-concentrated insulin candidate in type 2 diabetic patients. This means that Arecor can now initiate the second phase I clinical trial for AT278, to further explore the potential for AT278, it says. "With regulatory approval to commence our second clinical trial for AT278, we can continue the rapid progress we are making across our proprietary diabetes-focused portfolio. With its very promising profile already demonstrated in our previous study, AT278 has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid-acting insulin and to become the gold standard insulin for the growing population of people with diabetes with high daily insulin needs as well a critical enabler in the development of next-generation miniaturised insulin delivery systems," CEO Sarah Howell says.
----------
Baillie Gifford European Growth Trust PLC - aims for capital growth over long term from European securities - Net asset value per share total return amounts to negative 40.4%, underperforming its comparative index, which returned negative 15.3%. Net revenue for the year to September 30 totals 0.79 pence per share versus 0.44 pence. Explains that the largest detractors in its portfolio were Zalando SE, an online fashion retailer, Takeaway.com, an online food delivery service; and Wizz Air Holdings PLC, a low-cost airline. Recommends a final dividend of 0.70 pence per share, up from 0.35p.
----------
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.